News

Latest news

16th April 2024

Acticor Biotech will present the clinical results of its phase 2/3 ACTISAVE study in the treatment of stroke at ESOC 2024

Read more
22nd March 2024

SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 11.5 MILLION IN AN EQUITY PLACEMENT

Read more
15th March 2024

Acticor Biotech completes a capital increase for a total gross amount of 8 million euros

Read more
26th January 2024

Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure

Read more
26th January 2024

PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions

Read more
4th January 2024

Sequana Medical granted US CPT® III reimbursement codes for alfapump® system

Read more
30th November 2023

Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure

Read more
30th November 2023

Acticor Biotech completes a capital increase for a total gross amount of approximately 2.6 million euros, via the issuance of 850,360 shares

Read more
29th November 2023

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target

Read more